Corvus Pharmaceuticals Stock Rises on Positive Soquelitinib Trial Data

Corvus Pharmaceuticals shares are trading higher after the company announced favorable interim data from its Phase 1 trial of soquelitinib for atopic dermatitis, demonstrating a strong safety and efficacy profile.